GSK Gets Renewed Invitation to Human Genome Sciences Strategic Review
06/15/2012| 10:28am US/Eastern
LONDON--Pharmaceutical company GlaxoSmithKline PLC (>> GlaxoSmithKline plc) Friday confirmed that it has received a renewed invitation from Human Genome Sciences (>> Human Genome Sciences) to participate in its strategic alternatives review process which started in April, and said it is continuing with its tender for the company.
-GSK continues to believe that participation in the process is unnecessary given the company's offer is not conditioned on due diligence or financing and can be completed expeditiously.
-Shares at 1405 GMT down 0.7%, at 1,449 pence valuing the company at GBP72.6 billion.
-Write to Ed Ballard at firstname.lastname@example.org